Quantcast

Latest Novartis Stories

2014-04-03 08:29:00

- More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways EAST HANOVER, N.J., April 3, 2014 /PRNewswire/ -- Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research (AACR), April 5-9, 2014 in San Diego, CA. The AACR annual meeting highlights basic, translational...

2014-03-28 12:22:04

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/44vxfn/investigation ) has announced the addition of the "Investigation Report on China Imatinib Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Incidence of chronic myelogenous leukemia (CML) varies in the world. The global incidence is about 10/1,000,000 while in China it is 4/1,000,000. CML takes up about 20% of leukaemia in China...

2014-03-28 08:26:24

GAITHERSBURG, Md., March 28, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012. GenVec ended the year with $6.1 million in cash, cash equivalents, and short-term investments. "Over the past six...

2014-03-26 12:26:51

BOSTON, March 26, 2014 /PRNewswire/ -- CBI is pleased to announce that Pharmaceutical Executive will reveal its prestigious Brand of the Year Award during iPharma 2014 - industry's leading marketing innovation summit - taking place May 8-9, 2014 in New York, NY. iPharma 2014 is the most compelling and comprehensive life sciences meeting, uniting key stakeholders in the world of digital marketing, strategy, branding, innovation, media, and IT to share the latest trends and real-world...

2014-03-25 08:32:50

BASEL, Switzerland, March 25, 2014 /PRNewswire/ -- Syngenta today announced the successful issue of CHF 750 million in Swiss domestic bonds. This issue comprises a CHF 350 million Swiss domestic bond with maturity date in November 2019, a CHF 250 million Swiss domestic bond with maturity date in November 2024 and a CHF 150 million Swiss domestic bond with maturity date in November 2029. John Ramsay, CFO, said: "We have taken advantage of current favorable...

2014-03-24 12:30:48

BASEL, Switzerland, March 24, 2014 /PRNewswire/ -- Syngenta announced today the successful issue of EUR 750 million in Eurobonds. This issue comprises a EUR 500 million Eurobond with maturity date in November 2021 and a EUR 250 million Eurobond with maturity date in October 2017. John Ramsay, CFO, said: "We have taken advantage of current favorable market conditions in order to further enhance our debt maturity profile. These bond issues are part of our...

2014-03-21 16:23:03

- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years EAST HANOVER, N.J., March 21, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair(®) (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with...

2014-03-19 04:20:42

BASEL, Switzerland, March 19, 2014 /PRNewswire/ -- Syngenta today announced that its 2013 Annual Report is now available at www.syngenta.com/ar2013. The 2013 Annual Report consists of the following documents: -- Annual Review, incorporating the Corporate Responsibility Report -- Financial Report -- Corporate Governance and Compensation Report All documents are in English and German except for the Financial Report, which is published in English only. Printed copies of these...

2014-03-18 12:32:29

LONDON, March 18, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis World Adult Vaccines Market - Market OverviewFor much of the 20th century, vaccines were a pharmaceutical success story largely associated with children. Aggressive immunization programs eradicated Polio and Smallpox among developed nations and nearly eliminated Mumps, Pertussis, Measles,...

2014-03-12 08:31:21

ATLANTA, March 12, 2014 /PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced the promotion of Mike Sullivan to the position of President. Sullivan joined Avion Pharmaceuticals in 2011 as Vice President of Sales and Marketing. Tapped for his expertise in building corporate "start-up" pharmaceutical organizations, he has been instrumental in the commercial development, infrastructure and successful launch of Avion over the past three years....


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related